why choose us

First received: November 16, 2022

Clinical Trial: Life's End Benefits of Cannabidiol and Tetrahydrocannabinol

Study Status: Completed

Recruit Status: RECRUITING

Condition: Agitation

Study Type: INTERVENTIONAL


Official Title: Life's End Benefits of CannaBidiol and TetrahYdrocannabinol (LiBBY)

Brief Summary: This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks.This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks.This study will enroll approximately 150…

Read more